Navigation Links
HTRF IP-One Assay Performed on the PHERAstar and RUBYstar Plate Readers

Marjan Orban1, Francois Degorce2 and Jean-Luc Tardieu2
1BMG LABTECH, Germany; 2Cisbio international, France


Application Note 137 Rev. 12/2005

  • HTRF IP-One assay for Gq pathway investigation under HTS conditions
  • Comparable performance of PHERAstar and RUBYstar with the HTRF IP-One assay in terms of EC50 and Z' (> 0.78)
  • Comprehensive list of GPCRs already validated with IP-One assay for agonist responses

  • Introduction
    HTRF (homogeneous time-resolved fluorescence) technology, developed by Cisbio international, is used in assay development and drug screening. HTRF is based on FRET between a Eu3+ cryptate (donor) and a second fluorescent label (acceptor). A new acceptor, d2, allows the introduction of a complete GPCR (G protein-coupled receptor) platform suitable for drug discovery.

    Upon activation, GPCRs carry the information within the cell via two major signalling pathways: the activation of Gαs or Gαi coupled GPCRs results in a variation of the cAMP level, whereas the activation of Gq coupled GPCRs result in a transient increase of intracellular Ca2+ triggered by inositol (1,4,5) tri-phosphate (IP3). Cyclic AMP and IP3 therefore represent two essential secondary messengers for monitoring the activity of most GPCRs.

    Concerning the Gq pathway, the precursor molecule for the signaling cascade, IP3, is an extremely instable product (turnover only a few tens of seconds) and its degradation is irreversible. This of course has tended to make its detection highly inaccurate. IP3 induces a transient calcium release in the cell. Calcium sensing, through a very remote indicator, can allow the high throughput investigation of GPCR activity. To date, there has been no widespread use of IP assays in HTS, given its extremely challenging implementation. For lack of better options, the reference method consists of an assay which detects the accumulation of the cascades different inositol phosphates (IP3, IP4, IP2 and IP1) after the radioactive precursors uptake and a separation by affinity.

    Recently Cisbio launched a major new kit, HTRF IP-One, for Gq pathway investigation under HTS conditions. The IP-One kit allows the quantification of the cellular accumulation of inositol 1 phosphate (IP1).

    This application note focuses on the IP1 assay which has been validated on a broad and representative selection of Gq coupled receptors using the dedicated HTRF plate reader RUBYstar and the multimode plate reader PHERAstar from BMG LABTECH. These HTRF certified compatible readers are capable to simultaneously detect the fluorescence at two wavelengths (620 nm and 665 nm) and further signal ratioing also enables the technology to overcome interference from the medium or from compounds. Such technological efficiency, combined with the use of a high-affinity monoclonal antibody, give the assay all the qualities necessary for an HTS tool, particularly in terms of sensitivity, robustness and reliability.


    Assay Principle
    As previously mentioned, IP3, though, being the top choice as a secondary messenger for the Gq signaling pathway, nevertheless does not possess the necessary profile for an HTS tool because of its overlybrief physiological existence. Moreover, there is no inhibitor available for the phosphatases which convert IP3 into IP2 and then into IP1. On the other hand, the final stage of the cascade when IP1 is transformed into myo-inositol can be blocked with the use of LiCl, which enables one of the Gq pathways essential sub-products to be stabilized (figure 1), just as IBMX action prevents cAMP degradation. In its final configuration, it brings into play a highly specific MAb coupled to europium cryptate and the IP1 conjugated to the new HTRF acceptor, d2. This tiny proprietary molecule, with photophysical characteristics similar to those of XL665 (the reference HTRF acceptor), improves the technologys performances markedly, particularly in terms of IC50 stability and of measurement dynamics.


    Materials and Methods
    Cisbios homogeneous IP-One assay can be carried out in a single microplate, into which the cells have been dispensed the day before the actual test is run (figure 2). The cell stimulation conditions meet the particular characteristics of the cell line used - generally 30 minutes at 37C. Quantification of the accumulated IP1 is obtained after dispensing the two diluted conjugates into the lysis solution. Measurements can then start to be taken after just one hour of incubation, and be repeated as many times as necessary without impacting final data (e.g. IC50). The standard curve for the kit was run according to the package insert protocol in white 384-well plates (COSTAR cat# 3711384) with 20 L total assay volume. The HTRF signal was read on the PHERAstar and the RUBYstar.


    Cells were kindly provided by the Institut de Genomique Fonctionnelle (IGF), Montpellier, France and Euroscreen, Gosselie, Belgium. IP-One kit was supplied from Cisbio international (France). The dedicated plate reader RUBYstar and the multimode plate reader PHERAstar were purchased from BMG LABTECH (Germany).

    Cell lines (see table 1) expressing the GPCR target of interest were used for measuring IP1 production by stimulation of the ligand. In a 384-well format, the cell suspension was dispensed at 15,000 cells/ 20 L/well. After incubation at 37C, the culture supernatants were completely discarded. Then immediately after, 10 L of stimulation buffer containing various concentrations of ligand were added. After incubation at 37C for 1hr, 5 L IP1-d2 conjugate followed by 5 L of Eu-cryptate labeled anti-IP1 antibody were added. Time-resolved fluorescence at 620 nm and 665 nm were measured with PHERAstar and RUBYstar after incubation at 4C overnight, and the ratios of the signals and Delta F were calculated.

    Delta F % = [(Standard or sample Ratio Rationeg ) / Rationeg ] x 100


    Results and Discussion
    As shown in table 1, IP-One has already been validated on different models and targets - even if the cell lines involved were not specifically optimized for IP-One assay.


    The validations also conclusively demonstrate the assays performances in the presence of cell lines using Gα16 or Gqi9 type chimeric constructions. The IP-One assay showed equally good performance on different cellular backgrounds, stable or transient transfected cells, and chimeric constructs. There is a strong correlation with reference methods and no cross reactivity with 50 M of the following (phospho) inositides phosphates could be observed: Myo-inositol, PIP2, PIP3, IP2, IP3 and IP4.

    In addition, for a direct performance comparison of BMG LABTECHs PHERAstar with the RUBYstar the IP-One assay was applied upon the 1321N1-CCK1 cell line together with the agonist CCK8-sulfated. The experiment was performed in 96-well plates resulting in very close EC50 values and a very good correlation regarding the %inhibition / basal curve (figure 3). Z' calculations at an agonist concentration equal to EC80 resulted in Z' > 0.78 for both plate readers.


    But reaching beyond these expected results, the IP-One assay has already proved its worth in the field of screening for inverse agonist compounds. Looked at closely, and given its transitory characteristics, calcium measurement is often not sensitive enough to specifically detect the inhibition of the GPCR constitutive activities, whereas a modulation in the concentration of IP1 is perfectly able to show this. Using the IP-One assay therefore represents a tempting new alternative when investigating Gq-coupled receptors via the quantification of a new secondary messenger for this pathway, IP1. The messengers stability opens the possibility of the IP-One assays application to cases where other HTS technologies fail to provide a satisfactory solution such as in the detection of inverse agonist activities. The assay also profits from the special qualities of d2, one of the latest improvements implemented in HTRF technology. Given its performance, d2 is now included in all HTRF cAMP assays. The new HTRF platform for GPCR screening will thus incorporate a series of HTS assays, all using similar protocols and a standard robotics and detectors. Such a platform obviously holds all that is needed to provide test solutions which are particularly well-adapted to meeting the challenges of the different stages of drug screening.


    Conclusion
    Cisbios new IP-One assay, which is based on its proprietary HTRF technology, is the first high throughput system that can easily detect inositol(1)phosphate (IP1), one of the major products of the phosphatidyl inositol cascade, which tightly correlates with Gq-coupled activity. In association with Cisbios cAMP assay, it allows the establishment of a complete HTRF based GPCRs platform fully covering the different signalling pathways triggerred by GPCRs. All HTRF IP-One assay results were produced on BMG LABTECHs dedicated HTRF plate reader RUBYstar and the multimode plate reader PHERAstar. The readers showed in a comparison strongly correlating results in terms of EC50 and Z' values.


    back to top


    '"/>

    Source:


    Page: All 1 2 3 4 5 6

    Related biology technology :

    1. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
    2. Luminol-enhanced Assay for Superoxide Anion (O2 face="Symbol" )
    3. Organize Your Data from the Big Blue Mutation Assay
    4. Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations
    5. RNase Protection Assay (RPA) Using DIG-Labeled RNA Probes
    6. measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay
    7. Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success
    8. Using Validated siRNAs in Functional Genomic Assays
    9. Nuclease Protection Assays: The Basics
    10. RNArticles: RNA Amplification Used to Develop a New In Vitro HCMV Assay
    11. Detection of Phosphorylated and Total ERK and p38 MAPK by Bio-Plex Assay, ELISA, and Western Blotting, Rev A
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    TAG: HTRF One Assay Performed the PHERAstar and RUBYstar Plate Readers

    (Date:11/26/2014)... West Chester, OH (PRWEB) November 25, 2014 ... International Holdings, has joined the Graphel Carbon Products team ... experience in sales, marketing, and customer service for the ... to add Miles to our team,” stated Dave Trinkley, ... Products. “His wide range of experience in the ...
    (Date:11/26/2014)... 2014 Bio-Techne Corporation (NASDAQ: TECH ... Gavin to serve in a newly created position ... Mr. Gavin will be responsible for managing the operations ... ProteinSimple business acquired in July 2014 and the recently ... California -based ProteinSimple develops and commercializes proprietary systems ...
    (Date:11/24/2014)...  Last week, Representatives Gus Bilirakis ... a bold bipartisan step on behalf of patients ... Original co-sponsors of the legislation include Representatives McCaul ... drug makers and innovators to "repurpose" major market ... which opens the door to the development of ...
    (Date:11/24/2014)... Baltimore, MD (PRWEB) November 24, 2014 ... recruiting underrepresented patient populations into clinical trials at ... Maryland. , “Continental was created with the ... trials play a fundamental role in medical advances," ... the Tuskegee syphilis experiment to the immortal cell ...
    Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
    ... -- PARIS, September 20, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
    ... a central alternative to petroleum-based energy production. However, current ... yield and is more expensive to mass-produce. In addition, ... on the environment is incomplete, experts say. To ... of solar power, a research team from Rochester Institute ...
    ... contribution to the accelerated development of new, safe ... in the US and around the world, will ... between Arizona State University and Quintiles ( www.quintiles.com ... is a leader in managing clinical research. ...
    Cached Biology Technology:Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 2Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 3Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 4Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 5Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 6Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 7Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 8Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 9Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 10Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 11Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 12Research team assesses environmental impact of organic solar cells 2Drug Development in Arizona Gets Boost Following ASU-Quintiles Agreement 2
    (Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
    (Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
    (Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
    Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
    ... Opening up a new door in synthetic biology, a ... produces a continuous supply of tiny lipid spheres that ... membrane. "Cells are essentially small, complex bioreactors enclosed by ... California, Irvine. "Effectively producing vesicles with lipid membranes that ...
    ... TEMPE, Ariz. Humans are having an effect on Earth,s ... the warming of the planet we are causing. Now you ... are leaving behind. The only question is how large of ... in the current issue of Science (Dec. 16, ...
    ... one step closer, thanks to a new twist on an ... Illinois researchers, led by professors Jianjun Cheng and Fei Wang, ... segments to cells. The team published its work in the ... these are new materials that could potentially be used for ...
    Cached Biology News:Researchers assess effects of a world awash in nitrogen 2Let's do the twist: Spiral proteins are efficient gene delivery agents 2Let's do the twist: Spiral proteins are efficient gene delivery agents 3
    Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
    Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
    Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
    DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    Biology Products: